Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2117-2123

  Kinoshita, T ^a,b   Muramatsu, R ^a   Fujita, T ^a   Nagumo, H ^a   Sakurai, T ^a   Noji, S ^a   Takahata, E ^a   Yaguchi, T ^a   Tsukamoto, N ^a   Kudo Saito, C ^a   Hayashi, Y ^c   Kamiyama, I ^b   Ohtsuka, T ^b   Asamura, H ^b   Kawakami, Yutaka ^a  

^a Division of Cellular Signaling   (Japan)

^b Division of Thoracic Surgery   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Histological type; Non small cell lung cancer; Prognostic factor; Smoking habit; Tumor infiltrating lymphocytes

Indexed keywords

CD20 ANTIGEN; FORMALDEHYDE; PARAFFIN; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNTING; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; SMOKING HABIT; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ADULT; AGED; CLASSIFICATION; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SMOKING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SMOKING;

EID: 85019841393     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw319     Document Type: Article

References (21)

1. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013; 31: 1021-1028
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
3. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
4. Kinoshita T, Ohtsuka T, Yotsukura M et al. Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Oncol 2015; 10: 619-628
5. Maeda R, Ishii G, Yoshida J et al. Influence of cigarette smoking on histological subtypes of stage I lung adenocarcinoma. J Thorac Oncol 2011; 6: 743-750
6. Deng L, Gyorffy B, Na F et al. Association of PDCD1 and CTLA-4 gene expression with clinicopathological factors and survival in non-small-cell lung cancer: results from a large and pooled microarray database. J Thorac Oncol 2015; 10: 1020-1026
7. Suzuki K, Kadota K, Sima CS et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013; 31: 490-498
8. Kinoshita T, Ishii G, Hiraoka N et al. Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma. Cancer Sci 2013; 104: 409-415
9. Randall TD, Kern JA. Tertiary lymphoid structures target the antitumor immune response to lung cancer. Am J Respir Crit Care Med 2014; 189: 767-769
10. Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410-4417
11. Schalper KA, Brown J, Carvajal-Hausdorf D et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015; 107
12. Zhuang X, Xia X, Wang C et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010; 18: 24-28
13. Donnem T, Hald SM, Paulsen EE et al. Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 2015; 21: 2635-2643
14. Wakabayashi O, Yamazaki K, Oizumi S et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94: 1003-1009
15. Mori M, Ohtani H, Naito Y et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 2000; 191: 113-118
16. Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2005; 2: 11-19
17. Sugiyama D, Nishikawa H, Maeda Y et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3 + CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 2013; 110: 17945-17950
18. Galon J, Pages F, Marincola FM et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205
19. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232: 199-209
20. Song Z, Yu X, Cheng G, Zhang Y. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med 2016; 14: 188
21. Takada K, Toyokawa G, Okamoto T et al. An immunohistochemical analysis of PDL1 protein expression in surgically resected small cell lung cancer using different antibodies and criteria. Anticancer Res 2016; 36: 3409-3412